News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Brazil recalled its ambassador to Argentina after Argentine President Javier Milei publicly attacked President Lula and Brazil's judiciary, raising regional diplomatic tensions.
  • Citi expects the Federal Reserve to keep interest rates unchanged at its July meeting, a result investors will view as dovish.
  • Kevin Warsh urged the Fed to focus on underlying inflation measures instead of headline PCE, signaling debate over policy benchmarks.
  • ETF assets in Brazil rose to about 116 billion reais, nearly tripling in two years as investors favored tax-efficient fixed-income products.
  • Major asset managers expanded ETF operations in Brazil to meet demand, increasing supply of fee-efficient fixed-income vehicles.

Latest Articles

Kingstone Announces Date for 2026 Annual Meeting of Stockholders

Kingstone Announces Date for 2026 Annual Meeting of Stockholders

Kingstone Companies, Inc., a regional property and casualty insurance holding company, announced that its 2026 Annual Meeting of Stockholders will be held virtually on August 5, 2026. Shareholders of record as of June 12, 2026, can participate and vote at the meeting. Kingstone operates primarily through its subsidiary Kingstone Insurance Company, …

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Silexion Therapeutics announced a 1-for-10 reverse share split effective May 28, 2026, aimed at satisfying Nasdaq's minimum bid price requirement to preserve its listing and reinforce its capital structure. The company is advancing its lead RNA interference cancer therapy, SIL204, into a Phase 2/3 trial for locally advanced pancreatic cancer, with …

Braiin Partners with Switchcraft to Embed Utility and Telecom Switching Across Its UK Living Infrastructure Platform Targeting The Estimated £25 Billion UK Residential Lifecycle Services Market

Braiin Partners with Switchcraft to Embed Utility and Telecom Switching Across Its UK Living Infrastructure Platform Targeting The Estimated £25 Billion UK Residential Lifecycle Services Market

Braiin Limited announced a strategic partnership with Switchcraft to embed utility and telecom switching capabilities into its UK Living Infrastructure platform. This integration allows users to manage household services such as electricity, gas, broadband, and telecom directly through Braiin's platform, enhancing customer experience and unlocking …

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx announced promising pharmacokinetic and pharmacodynamic data from a sub-study of their ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine delivery using their TAMP platform and RenovoCath device. The study demonstrated potential for increased local drug potency with reduced systemic exposure and side effects c…

Linkage Global Inc. Announces $8 Million Share Repurchase Program

Linkage Global Inc. Announces $8 Million Share Repurchase Program

Linkage Global Inc., a cross-border e-commerce integrated services company, has announced an $8 million share repurchase program following its recent rebranding and Nasdaq ticker change to UZX. The repurchase program authorizes the company to buy back its Class A shares via various means, signaling management's confidence in its evolving business m…

PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study

PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study

PRF Technologies announced successful preclinical results demonstrating that its lead product candidate, PRF-110, achieved sustained analgesic activity comparable to the approved extended-release product ZYNRELEF in a 72-hour post-surgical evaluation. PRF-110 is a ropivacaine-only, NSAID-free extended-release formulation aimed at post-operative pai…

Beeline Holdings Added to Membership of Russell Microcap® Index

Beeline Holdings Added to Membership of Russell Microcap® Index

Beeline Holdings, a digital mortgage platform, will be added to the Russell Microcap Index effective June 29, 2026, following the reevaluation of the Russell US Indexes. This inclusion is expected to increase liquidity in Beeline's stock and attract a broader institutional investor base. Russell indexes are widely used benchmarks with over $12 tril…

FAST TRACK GROUP Subsidiary Partners with South Korean Celebrity Amotti for Resorts World Sentosa’s “Paws for a Cause” CSR Event

FAST TRACK GROUP Subsidiary Partners with South Korean Celebrity Amotti for Resorts World Sentosa’s “Paws for a Cause” CSR Event

Fast Track Group's subsidiary, Fast Track Entertainment, partnered with South Korean fitness celebrity Amotti as the official talent and consultation partner for Resorts World Sentosa's 'Paws for a Cause' charity dog walk event. This collaboration underscores the company's strategy to deepen celebrity partnerships in Asia and enhance meaningful bra…

Enlight Signs 200 MW AC Solar Power Purchase Agreement with Google to Support Data Center Operations in Oklahoma

Enlight Signs 200 MW AC Solar Power Purchase Agreement with Google to Support Data Center Operations in Oklahoma

Enlight Renewable Energy's U.S. subsidiary Clēnera Holdings has signed a 15-year power purchase agreement with Google, committing 200 MW AC solar energy from the 250 MW DC Solstice project in Oklahoma. Construction is expected to start in 2028 with operations targeted in 2029, including potential battery storage expansion. This marks Enlight's firs…

Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System

Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System

Microbot Medical Inc. announced it has received regulatory clearance from the Israeli Ministry of Health for its LIBERTY Endovascular Robotic System, marking the first approval outside the U.S. This clearance allows commercial marketing in Israel and supports further international expansion with a Free Sale Certificate. The company is also pursuing…

Analysts Start Coverage on Pershing Square with Measured Optimism

Analysts Start Coverage on Pershing Square with Measured Optimism

Two major brokerages opened coverage on Pershing Square Inc., praising the firm’s permanent capital base, compact operating model and long-term performance while cautioning that the stock’s valuation already embeds significant expectations. RBC Capital Markets and Wells Fargo Securities each set neutral-style initial ratings and price targets, and …

Hyperfine Shares Rise Ahead of Anticipated Russell 2000 Inclusion

Hyperfine Shares Rise Ahead of Anticipated Russell 2000 Inclusion

Hyperfine Inc. saw its stock trade higher in premarket activity after a preliminary list from FTSE Russell indicated the company is expected to be added to the Russell 3000 and Russell 2000 indexes at the conclusion of the June 2026 reconstitution. The addition becomes effective after the U.S. market close on June 26, 2026. The company makes the Sw…

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

Clearmind Medicine Inc. announced that Johns Hopkins Medicine Institutional Review Board has approved the advancement of its Phase I/II clinical trial for CMND-100, a non-hallucinogenic neuroplastogen drug candidate aimed at Alcohol Use Disorder (AUD). The approval enables the company to proceed to critical Parts B and C of the multicenter study, m…

Nocera Shares Rally After Move to Become Diversified Tech Holding Company

Nocera Shares Rally After Move to Become Diversified Tech Holding Company

Nocera Inc (NASDAQ:NCRA) saw its stock jump 180% in premarket trading after unveiling plans to transition into Nocera Holdings, a diversified, technology-focused holding company. The firm expanded permitted uses of a previously announced up-to-$300 million financing facility to include acquisitions, strategic investments, partnerships and working c…